IMRX...$4.65...🥳...Next leg up here...
georgie18
Member Level
Re: georgie18 post# 689271
Tuesday, July 22, 2025 8:37:30 AM
Post#
690631
of 690834
IMRX...$4.08...🥳... https://schrts.co/cNbCdwhW ...Bullish Harami Cross...100/200 Cross...Ready for next leg up...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 395205
Monday, July 14, 2025 11:31:35 AM
Post#
395400
of 395813
IMRX...$4.04...🥳...Watching for another entry...Ran from $1 range to $4.50 range
georgie18
Member Level
Re: georgie18 post# 689271
Tuesday, July 22, 2025 8:37:30 AM
Post#
690631
of 690834
IMRX...$4.08...🥳... https://schrts.co/cNbCdwhW ...Bullish Harami Cross...100/200 Cross...Ready for next leg up...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 395205
Monday, July 14, 2025 11:31:35 AM
Post#
395400
of 395813
IMRX...$4.04...🥳...Watching for another entry...Ran from $1 range to $4.50 range
Recent IMRX News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/20/2026 08:16:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/20/2026 08:10:12 PM
- Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond • GlobeNewswire Inc. • 04/20/2026 01:00:00 PM
- Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/06/2026 08:05:00 PM
- Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival • GlobeNewswire Inc. • 03/17/2026 08:35:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2026 01:29:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:09:20 PM
- Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/06/2026 12:45:00 PM
- Immuneering to Present at the Leerink Global Healthcare Conference • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:44:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:37:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:32:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:22:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:14:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:10:18 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/22/2026 02:03:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 02:09:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:07:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/15/2026 01:06:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 01:10:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2026 09:10:10 PM
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP • GlobeNewswire Inc. • 01/07/2026 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 09:50:06 PM
- Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 • GlobeNewswire Inc. • 12/23/2025 01:00:00 PM
